Omkar Pharmachem Ltd
₹ 29.5
-0.81%
16 Feb 2026
- Market Cap ₹ 29.8 Cr.
- Current Price ₹ 29.5
- High / Low ₹ 30.1 / 25.5
- Stock P/E 331
- Book Value ₹ 9.43
- Dividend Yield 0.00 %
- ROCE 3.04 %
- ROE 2.14 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- Stock is trading at 3.13 times its book value
- Promoter holding is low: 0.03%
- Company has a low return on equity of 2.15% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Commodity Chemicals
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.07 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.27 | 0.54 | 0.54 | 0.54 | 0.54 | 0.53 | |
| 0.07 | 0.06 | 0.12 | 0.22 | 0.24 | 0.38 | 0.26 | 0.24 | 0.27 | 0.22 | 0.25 | 0.24 | 0.31 | |
| Operating Profit | 0.00 | -0.06 | -0.12 | -0.22 | -0.24 | -0.38 | -0.21 | 0.03 | 0.27 | 0.32 | 0.29 | 0.30 | 0.22 |
| OPM % | 0.00% | -420.00% | 11.11% | 50.00% | 59.26% | 53.70% | 55.56% | 41.51% | |||||
| 0.00 | 0.00 | 0.00 | 0.49 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.04 | 0.05 | 0.06 | 0.06 | 0.05 | 0.03 | 0.02 | 0.02 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 |
| Profit before tax | 0.00 | -0.06 | -0.12 | 0.27 | -0.25 | -0.42 | -0.26 | -0.03 | 0.21 | 0.27 | 0.26 | 0.27 | 0.20 |
| Tax % | 0.00% | 0.00% | 18.52% | 0.00% | 0.00% | 0.00% | -866.67% | 14.29% | 25.93% | 23.08% | 25.93% | ||
| 0.00 | -0.06 | -0.12 | 0.22 | -0.26 | -0.42 | -0.26 | 0.22 | 0.18 | 0.20 | 0.19 | 0.20 | 0.09 | |
| EPS in Rs | 0.00 | -0.06 | -0.12 | 0.22 | -0.26 | -0.42 | -0.26 | 0.22 | 0.18 | 0.20 | 0.19 | 0.20 | 0.09 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 61% |
| 3 Years: | 0% |
| TTM: | -5% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 23% |
| 3 Years: | 4% |
| TTM: | -55% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | 7% |
| 3 Years: | 6% |
| 1 Year: | -2% |
| Return on Equity | |
|---|---|
| 10 Years: | 0% |
| 5 Years: | 2% |
| 3 Years: | 2% |
| Last Year: | 2% |
Balance Sheet
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 | 10.08 |
| Reserves | -0.75 | -0.81 | -0.93 | -0.71 | -0.96 | -1.38 | -1.64 | -1.42 | -1.24 | -1.04 | -0.85 | -0.65 | -0.57 |
| 0.01 | 0.01 | 0.00 | 0.00 | 0.24 | 0.58 | 0.87 | 0.90 | 0.93 | 0.62 | 0.30 | 0.12 | 0.00 | |
| 0.11 | 0.13 | 0.57 | 0.06 | 0.04 | 0.05 | 0.06 | 0.08 | 0.06 | 0.07 | 0.07 | 0.05 | 0.04 | |
| Total Liabilities | 9.45 | 9.41 | 9.72 | 9.43 | 9.40 | 9.33 | 9.37 | 9.64 | 9.83 | 9.73 | 9.60 | 9.60 | 9.55 |
| 0.01 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.01 | 0.01 | 0.01 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 | 9.30 |
| 0.14 | 0.10 | 0.41 | 0.13 | 0.09 | 0.03 | 0.07 | 0.34 | 0.52 | 0.43 | 0.29 | 0.29 | 0.24 | |
| Total Assets | 9.45 | 9.41 | 9.72 | 9.43 | 9.40 | 9.33 | 9.37 | 9.64 | 9.83 | 9.73 | 9.60 | 9.60 | 9.55 |
Cash Flows
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | -0.05 | 0.34 | -0.77 | -0.25 | -0.30 | -0.21 | 0.02 | 0.20 | 0.28 | 0.30 | 0.24 | |
| 0.00 | 0.00 | 0.00 | 0.49 | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 | 0.00 | -0.01 | 0.00 | |
| 0.00 | 0.00 | -0.01 | 0.01 | 0.23 | 0.30 | 0.24 | -0.02 | -0.03 | -0.35 | -0.35 | -0.20 | |
| Net Cash Flow | 0.01 | -0.05 | 0.33 | -0.28 | -0.03 | 0.00 | 0.02 | 0.00 | 0.17 | -0.08 | -0.06 | 0.04 |
| Free Cash Flow | 0.01 | -0.05 | 0.34 | -0.29 | -0.26 | -0.30 | -0.21 | 0.02 | 0.19 | 0.28 | 0.29 | 0.24 |
| CFO/OP | 83% | -283% | 327% | 104% | 79% | 100% | 67% | 74% | 88% | 103% | 80% |
Ratios
Figures in Rs. Crores
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 365.00 | 146.00 | 40.56 | 54.07 | 87.87 | 33.80 | 67.59 | |||||
| Inventory Days | ||||||||||||
| Days Payable | ||||||||||||
| Cash Conversion Cycle | 365.00 | 146.00 | 40.56 | 54.07 | 87.87 | 33.80 | 67.59 | |||||
| Working Capital Days | -52.14 | -6,570.00 | -1,270.74 | -608.33 | -378.52 | -162.22 | -6.76 | |||||
| ROCE % | 0.00% | -0.64% | -1.30% | -2.27% | -2.56% | -4.08% | -2.26% | 0.32% | 2.79% | 3.29% | 3.02% | 3.04% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Operating Segments Number |
|
|||||||||||
| Number of Permanent Employees Number |
||||||||||||
Requires Premium
Requires Premium
Documents
Announcements
- Closure of Trading Window 25 Mar
- Newspaper Publication Regarding Special Window For Transfer And Dematerialization (Demat) Of Physical Shares 25 Mar
-
Additional Details Required For Corporate Announcement Filed Under Regulation 30 Of SEBI (LODR) Regulations, 2015
16 Feb - Clarification: Independent Director Janak Raj Sharma ceased effective 12-Feb-2026; intimation filed 14-Feb-2026.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
16 Feb - Dear Sir, Please find Newspaper Advertisement for the Unaudited Financial Results for the quarter and nine months ended on 31.12.2025.
-
Unaudited Financial Results For The Quarter And Nine Months Ended On 31.12.2025
14 Feb - Omkar Pharmachem files unaudited results for quarter/nine months ended 31-12-2025: nine-month profit Rs 10.68 lakh
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2]
OPL is in the business of pharmaceuticals,
chemicals, including Specialty chemicals,
Ciba Specialty Chemicals, Organic chemicals, etc., and to provide management and business support services. Currently, the company is only
engaged in the business of providing support services related to activities.